Ireland-Switzerland Bilateral Trade Analysis 2023

Complete trade statistics: $8.14B total volume โ€ขIreland surplus: $2.48B

Ireland โ†’ Switzerland

$5.31B

Exports (2023)

Switzerland โ†’ Ireland

$2.83B

Imports (2023)

Trade Balance

$2.48B

Surplus for Ireland

Total Trade

$8.14B

Combined Volume

Trade Flow Visualization

Direct trade relationship between Ireland and Switzerland. Green line shows exports from Ireland, red line shows imports.

Detailed Product Trade Analysis

Comprehensive breakdown of trade flows by product category, revealing the specialized nature of the Ireland-Switzerland commercial relationship and competitive positioning in global markets.

Ireland โ†’ Switzerland Exports

$5.31B
2023 Total

Export Market Intelligence

Product Diversity:
Highly Diversified
Market Share:
28.0% top product
1Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale
$1.49B
28.0% of exports
2Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions
$1.41B
26.7% of exports
3Medicaments: consisting of mixed or unmixed products n.e.c. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale
$363.31M
6.8% of exports
4Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) and clobazam (INN) and methyprylon (INN)
$331.28M
6.2% of exports
5Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea and its derivatives, loprazolam, mecloqualone, methaqualone, zipeprol, and salts thereof) n.e.c. in 2933.5
$314.48M
5.9% of exports
6Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale
$237.14M
4.5% of exports
7Medical, surgical instruments and appliances: catheters, cannulae and the like
$101.60M
1.9% of exports
8Units of automatic data processing machines: processing units other than those of item no. 8471.41 or 8471.49, whether or not containing in the same housing one or two of the following types of unit: storage units, input units or output units
$71.99M
1.4% of exports
9Heterocyclic compounds: n.e.c. in headings no. 2933
$55.41M
1.0% of exports
10Aeroplanes and other aircraft: of an unladen weight exceeding 15,000kg
$53.60M
1.0% of exports

๐ŸŽฏ Strategic Export Focus

Ireland's export portfolio to Switzerland demonstrates strong diversification across multiple sectors, with blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale representing a key competitive advantage in this bilateral market.

Switzerland โ†’ Ireland Imports

$2.83B
2023 Total

Import Dependency Profile

Supply Diversity:
Well Diversified
Critical Imports:
34.2% concentration
1Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) and clobazam (INN) and methyprylon (INN)
$967.95M
34.2% of imports
2Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale
$211.46M
7.5% of imports
3Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea and its derivatives, loprazolam, mecloqualone, methaqualone, zipeprol, and salts thereof) n.e.c. in 2933.5
$195.62M
6.9% of imports
4Pacemakers: for stimulating heart muscles (excluding parts and accessories)
$152.85M
5.4% of imports
5Medicaments: consisting of mixed or unmixed products n.e.c. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale
$142.11M
5.0% of imports
6Heterocyclic compounds: containing an unfused thiazole ring (whether or not hydrogenated) in the structure
$104.49M
3.7% of imports
7Wrist-watches: electrically operated, with or without a stop-watch, (other than those of heading no. 9101) with mechanical display only
$83.40M
2.9% of imports
8Wrist-watches: whether or not incorporating a stop-watch facility, with automatic winding
$74.87M
2.6% of imports
9Medical, surgical instruments and appliances: catheters, cannulae and the like
$74.77M
2.6% of imports
10Heterocyclic compounds: n.e.c. in headings no. 2933
$51.14M
1.8% of imports

๐Ÿ“ฆ Import Strategy Analysis

Ireland's import pattern from Switzerland reveals significant dependencyin heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) and clobazam (inn) and methyprylon (inn), highlighting complementary economic structures and potential supply chain optimization opportunities.

Competitive Trade Position Analysis

๐Ÿ†

Market Leadership

Ireland demonstrates competitive strength in exportingblood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale to Switzerland, leveraging comparative advantages.

Export Leader in 20+ Categories
๐Ÿ”„

Trade Complementarity

The bilateral relationship showsmoderatecomplementarity, with each country specializing in different sectors.

Specialized Exchange
๐Ÿ“ˆ

Growth Potential

The $8.14B trade volume indicates substantial economic integration with room for expansion in emerging sectors.

Significant Partnership

Executive Summary: Ireland-Switzerland Trade Relationship

Key Trade Highlights 2023

  • Total Trade Volume: $8.14 billionrepresenting a significant bilateral economic relationship
  • Trade Balance: Ireland maintains a surplus of $2.48 billion
  • Export Focus: Ireland's primary exports include blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale, blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions, medicaments: consisting of mixed or unmixed products n.e.c. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale
  • Import Dependencies: Key imports from Switzerland include heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) and clobazam (inn) and methyprylon (inn), blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale, heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea and its derivatives, loprazolam, mecloqualone, methaqualone, zipeprol, and salts thereof) n.e.c. in 2933.5

Strategic Trade Indicators

Trade IntensityHigh
Export DiversificationDiversified
Trade Balance HealthImbalanced

๐Ÿ“ˆ Market Position: This bilateral trade relationship represents an important regional trade partnerships, with complementary economic strengths driving sustained commercial exchange.

Historical Trade Analysis & Economic Context

Trade Evolution Timeline

2019-2023: Recent Trends

Current trade volume of $8.14B represents the culmination of evolving bilateral commercial relationships, influenced by global supply chain shifts and changing economic priorities.

2015-2019: Growth Period

Sustained expansion in bilateral trade driven by complementary economic structures, with Ireland leveraging its comparative advantages in blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale.

2010-2015: Foundation Building

Establishment of modern trade frameworks and reduction of barriers, facilitating increased commercial exchange and investment flows between the two economies.

Pre-2010: Early Development

Initial stages of bilateral trade relationship development, with focus on traditional export-import patterns and gradual market integration.

Key Economic Drivers

1

Comparative Advantage

Ireland's specialization in blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail salecomplements Switzerland's demand patterns, creating natural trade synergies.

2

Supply Chain Integration

Deep integration in global value chains has strengthened bilateral linkages, particularly in heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) and clobazam (inn) and methyprylon (inn).

3

Market Access & Trade Policy

Favorable trade agreements and market access conditions have facilitated the growth of this $8.14B bilateral relationship.

Trade Pattern Insights

Trade ComplementarityAsymmetric
Seasonal VariationsModerate
Product ConcentrationLow
Market DependencyHigh
๐Ÿ”ฎ

Trade Relationship Outlook

The $8.14B bilateral trade volume positions this relationship for continued growth, supported by technological advancement, evolving consumer preferences, and strengthening economic ties. Key opportunities lie in expanding cooperation in emerging sectors while managing potential supply chain vulnerabilities.

Economic Impact & Strategic Outlook

Economic Impact Assessment

๐Ÿ’ฐ

Trade Volume Impact

The $8.14 billion bilateral trade volume represents a important trade relationshipfor both economies.

Economic Significance: Moderate
๐Ÿญ

Industrial Integration

Trade flows in blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale and heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) and clobazam (inn) and methyprylon (inn) demonstrate deep industrial linkages and supply chain integration.

Supply Chain Integration: Diversified
โš–๏ธ

Trade Balance Effects

Ireland's trade surplus of $2.48 billion strengthens its overall economic position in this bilateral relationship.

Balance Impact: Export Advantage

Strategic Future Outlook

๐Ÿš€Growth Opportunities

Emerging Sectors
Technology transfer and innovation cooperation in blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions present expansion opportunities.
Market Diversification
Beyond current focus on heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) and clobazam (inn) and methyprylon (inn), new product categories offer potential for trade expansion.

โš ๏ธRisk Factors

Supply Chain Vulnerabilities
Moderate concentration in key sectors requires monitoring
Market Competition
Global competition in blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale may affect future market positioning.

๐ŸŽฏStrategic Recommendations

  • Strengthen cooperation in high-value sectors beyond current trade patterns
  • Develop alternative supply chains to reduce dependency risks
  • Explore joint ventures in emerging technology sectors
  • Enhance trade facilitation and reduce transaction costs

Market Position & Competitive Summary

The bilateral trade relationship between Ireland and Switzerland represents a total trade volume of $8.14 billion in 2023. This partnership demonstrates a favorable trade balance for Ireland, with exports exceeding importsby $2.48 billion.

Export Strengths

Ireland's exports to Switzerland total $5.31 billion, with competitive advantages in blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale, representing $1.49B or28.0% of bilateral exports.

Import Dependencies

Imports from Switzerland amount to $2.83 billion, highlighting economic interdependence in heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) and clobazam (inn) and methyprylon (inn), with Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) and clobazam (INN) and methyprylon (INN) comprising34.2% of total imports.

The trade relationship reflects broader economic patterns and comparative advantages. The trade surplus indicates Ireland's competitive position in this bilateral relationship. This partnership is characterized by complementary trade flows, with each country specializing in different product categories based on their respective economic strengths, industrial capabilities, and position in global value chains.

Download Bilateral Trade Data

Access detailed trade data between Ireland and Switzerland in multiple formats.

Data Source: CEPII BACI (Base pour l'Analyse du Commerce International) โ€ข Last Updated: January 2025 โ€ข Coverage: 1995-2023